Janssen Seeks Expedited Trial in Janssen v. Celltrion

Approved Biosimilar Products  •  Biosimilar News  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News

One week ago, we reported that FDA approved Celltrion’s Inflectra, a biosimilar to Janssen’s Remicade (infliximab).

Today, Janssen filed a letter to the court in Janssen v. Celltrion informing the court that the “Defendants notified us that they intend to begin commercial sales of their biosimilar in no later than 180 days (on October 2, 2016).”  In light of the court’s “general reluctance to issue a preliminary injunction and then issue a final decision on the merits at a later time,” Janssen decided to forgo seeking a preliminary injunction. Instead, Janssen requested that the court “hold an expedited trial on the merits” of the patent dispute “so that plaintiffs’ request for a permanent injunction can be adjudicated by October 2, 2016.”

Stay tuned for further coverage here at Big Molecule Watch.

Download PDF

Comments are closed.